It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative condition leading to progressive muscle weakness, atrophy, and ultimately death. Traditional ALS clinical evaluations often depend on subjective metrics, making accurate disease detection and monitoring disease trajectory challenging. To address these limitations, we developed the nQiALS toolkit, a machine learning-powered system that leverages smartphone typing dynamics to detect and track motor impairment in people with ALS. The study included 63 ALS patients and 30 age- and sex-matched healthy controls. We introduce the three core components of this toolkit: the nQiALS-Detection, which differentiated ALS from healthy typing patterns with an AUC of 0.89; the nQiALS-Progression, which separated slow and fast progression at specific thresholds with AUCs ranging between 0.65 and 0.8; and the nQiALS-Fine Motor, which identified subtle progression in fine motor dysfunction, suggesting earlier prediction than the state-of-the-art assessment. Together, these tools represent an innovative approach to ALS assessment, offering a complementary, objective metric to traditional clinical methods and which may reshape our understanding and monitoring of ALS progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Area 2 AI Corporation, Cambridge, USA; nQ Medical, Cambridge, USA
2 Healey & AMG Center for ALS, Massachusetts General Hospital, Department of Neurology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); University of Milan, Neurology Residency Program, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
3 Healey & AMG Center for ALS, Massachusetts General Hospital, Department of Neurology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
4 nQ Medical, Cambridge, USA (GRID:grid.32224.35); Simbec Orion, Wales, UK (GRID:grid.32224.35)
5 nQ Medical, Cambridge, USA (GRID:grid.32224.35); ProKidney Corporation, Winston-Salem, USA (GRID:grid.32224.35)
6 nQ Medical, Cambridge, USA (GRID:grid.32224.35)
7 Mitsubishi Tanabe Pharma Corporation, Osaka, Japan (GRID:grid.32224.35) (ISNI:0000 0004 0629 2251)
8 Mitsubishi Tanabe Pharma America, Inc, Jersey City, USA (GRID:grid.32224.35)
9 Area 2 AI Corporation, Cambridge, USA (GRID:grid.32224.35); nQ Medical, Cambridge, USA (GRID:grid.32224.35)
10 Healey & AMG Center for ALS, Massachusetts General Hospital, Department of Neurology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Mayo ALS Clinic, Scottsdale, USA (GRID:grid.32224.35)